Tivumecirnon clinical trials
Also written FLX475.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses tivumecirnon has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FLX475
- 2
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
RAPT Therapeutics, Inc. (2) · Hanmi Pharmaceutical Company Limited (1)
Studies
Open first, then newest update. How each study uses tivumecirnon has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedPhase 1/2RAPT Therapeutics, Inc.NCT03674567Written as FLX475 (tivumecirnon)How we knowReport a problem
- FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT04768686Written as FLX475How we knowReport a problem
- FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedPhase 2RAPT Therapeutics, Inc.NCT04894994Written as FLX475How we knowReport a problem
Tested with established drugs · 3 — they are given beside it
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedPhase 1/2RAPT Therapeutics, Inc.NCT03674567Written as FLX475 (tivumecirnon)How we knowReport a problem
- FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT04768686Written as FLX475How we knowReport a problem
- FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedPhase 2RAPT Therapeutics, Inc.NCT04894994Written as FLX475How we knowReport a problem
Codes
What other systems call tivumecirnon · ClinicalTrials.gg INT017745
- UNII (FDA) R1T69T65FJTIVUMECIRNONOne source FDA
- NCI Thesaurus C157240TivumecirnonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R1T69T65FJ | TIVUMECIRNON | One source FDA |
| NCI Thesaurus | C157240 | Tivumecirnon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.